UNC Chapel Hill scientists created a test that pinpoints human antibodies specific to a unique part of the SARS-CoV-2 spike protein. The test can help document COVID-19 infections, identify asymptomatic virus infection, and measure the level of immunity in individuals.
University of North Carolina School of Medicine researchers designed experiments using gene-editing tools to discover how molecules called gangliosides serve as de facto gatekeepers to allow hepatitis A virus entry into liver cells.
UAB’s Undergraduate Immunology Program, one of a handful of immunology majors available in the United States, gives students real lab experience with more than 100 faculty pursuing cutting-edge research.The entire planet, more or less, is fixated on the greatest pandemic in modern memory. Claire Elliott is already preparing for the next one.
Today, the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories received emergency use authorization from the U.S. Food and Drug Administration (FDA) for an antibody test that was developed, validated, and launched at Mount Sinai by a team of internationally renowned researchers and clinicians of the Icahn School of Medicine at Mount Sinai. This test detects the presence or absence of antibodies to SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) and importantly, may also be used to identify positive specimens with an antibody titer (level) up to a dilution of 1:2880 for the identification of individuals with higher antibody titers.